The clinical efficacy, safety and usefulness of cefoselis (FK 037, CFSL), a new parenteral cephalosporin, were evaluated in chronic respiratory tract infection in a comparative study with ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days. The following results were obtained. 1. A total of 167 patients were enrolled in this study. Efficacy rates ('good' and better responses) were 90.3% (65/72) in the CFSL group and 89.7% (61/68) in the CAZ group. 2. Bacteriological effects (eradication rates) were 89.2% (33/37) in the CFSL group and 94.1% (32/34) in the CAZ group. 3. Adverse reactions occurred in 6 of the 81 patients in the CFSL group and in 2 of the 76 patients in the CAZ group. The incidence of abnormal laboratory findings was 11.1% (9/81) in the CFSL group and 13.3% (10/75) in the CAZ group. 4. Usefulness rates ('useful' and better responses) were 84.9% (62/73) in the CFSL group and 86.8% (59/68) in the CAZ group. No significant difference was observed between the two groups in any of the above items. The results indicate that cefoselis is a useful drug in the treatment of chronic respiratory tract infections. This paper reports clinical results excluding cases violating Good Clinical Practice (GCP) found after publication of our previous paper in 'Jpn. J. Chemother.' (Vol. 43, No. 4, 1995).
|Number of pages||18|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 1996 Jul|
ASJC Scopus subject areas
- Pharmacology (medical)